Literature DB >> 8067696

Therapeutic efficacy and toxicity of sequential methotrexate and 5-fluorouracil in gastric cancer.

T Konishi1, M Hiraishi, K Mafune, T Miyama, T Hirata, K Mori, H Nishina, Y Idezuki.   

Abstract

The therapeutic efficacy and toxicity of sequential methotrexate and 5-fluorouracil in 64 inoperable gastric cancer patients are reported. An intermediate-dose treatment was given to 48 patients, and a low-dose treatment to 16 patients. In the intermediate-dose treatment, leukopenia was observed in 11 patients, nausea and vomiting in six patients and diarrhea and stomatitis in two patients each. In the low-dose treatment, no patient developed toxic symptoms of grade 3 or 4. All 9 responders had adenocarcinoma of the poorly differentiated type and the response rate in patients who belonged to this type was 32.1%.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8067696

Source DB:  PubMed          Journal:  Anticancer Res        ISSN： 0250-7005            Impact factor:   2.480


  6 in total

1.  Clinical significance of evaluating primary lesions in patients with gastric cancer who receive chemotherapy.

Authors:  Kento Nakatani; Wasaburo Koizumi; Katsuhiko Higuchi; Chikatoshi Katada; Toru Sasaki; Norisuke Nakayama; Satoshi Tanabe; Katsunori Saigenji
Journal:  Gastric Cancer       Date:  2010-04-07       Impact factor: 7.370

2.  A phase II study of combined chemotherapy with methotrexate, 5-fluorouracil, and low-dose cisplatin (MFP) for histologically diffuse-type advanced and recurrent gastric cancer (KDOG9501).

Authors:  Norisuke Nakayama; Wasaburo Koizumi; Satoshi Tanabe; Tohru Sasaki; Katsunori Saigenji
Journal:  Gastric Cancer       Date:  2006       Impact factor: 7.370

3.  Pilot study of a combination of S-1 and paclitaxel for patients with peritoneal metastasis from gastric cancer.

Authors:  Shigeyuki Tamura; Hirofumi Miki; Kaoru Okada; Atsushi Takeno; Kumiko Uji; Atsuko Yoshida; Rei Suzuki; Shin Nakahira; Chiyomi Egawa; Ken Nakata; Shu Okamura; Keishi Sugimoto; Yuichi Takatsuka
Journal:  Gastric Cancer       Date:  2010-07-03       Impact factor: 7.370

4.  Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407).

Authors:  Tomohiro Nishina; Narikazu Boku; Masahiro Gotoh; Yasuhiro Shimada; Yasuo Hamamoto; Hirofumi Yasui; Kensei Yamaguchi; Hiroki Kawai; Norisuke Nakayama; Kenji Amagai; Junki Mizusawa; Kenichi Nakamura; Kuniaki Shirao; Atsushi Ohtsu
Journal:  Gastric Cancer       Date:  2015-09-19       Impact factor: 7.370

5.  Intraperitoneal administration of paclitaxel and oral S-1 for a patient with peritoneal dissemination and hydronephrosis due to advanced gastric cancer.

Authors:  Shigeyuki Tamura; Hirofumi Miki; Ken Nakata; Daisuke Takiuchi; Kaoru Okada; Shin Nakahira; Shu Okamura; Keishi Sugimoto; Naohiro Tomita; Yuichi Takatsuka
Journal:  Gastric Cancer       Date:  2007-12-25       Impact factor: 7.370

6.  Sequential chemotherapy with methotrexate and 5-fluorouracil for chemotherapy-naive advanced gastric cancer with disseminated intravascular coagulation at initial diagnosis.

Authors:  Atsuo Takashima; Kuniaki Shirao; Yoshinori Hirashima; Daisuke Takahari; Natsuko T Okita; Takako E Nakajima; Ken Kato; Tetsuya Hamaguchi; Yasuhide Yamada; Yasuhiro Shimada
Journal:  J Cancer Res Clin Oncol       Date:  2010-02       Impact factor: 4.553
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.